Research by Chinese scientists, Qin et al., published in the Cell Metabolism journal, suggests that the active ingredient in many weight loss drugs, semaglutide, may reverse tissue damage caused by osteoarthritis. 

In both mouse models and a randomized human trial, semaglutide was shown to reduce pain and decrease cartilage degeneration by reprogramming metabolism of cells that synthesize and maintain healthy cartilage.  

While the trial should be interpreted with caution pending further validation by clinical trials, if correct, the findings could be highly relevant in personal injury cases, particularly where traumatic joint damage leads to the early onset or acceleration of osteoarthritis. 

Evidence that certain medications may promote cartilage repair could impact assessments of long‑term prognosis, future medical needs, and the valuation of ongoing damages related to joint deterioration.